Neurones (PA:NRO) — Stock Price
Neurones (PA:NRO) is currently trading at €39.00 EUR, up 3.04% today. Over the past 52 weeks, shares have ranged between €33.65 and €44.70. This page tracks Neurones's live share price on the PA exchange, its daily price and volume history, and — where reported — its income statement, balance sheet, cash flow statement, and earnings history. For company valuation and market capitalisation context, see Neurones (NRO) total market value.
Neurones (NRO) Stock Price Chart — Daily History & Trading Volume
The chart below tracks Neurones's daily closing share price and trading volume on the PA exchange over the past year, giving a clear view of recent price momentum and liquidity.
Neurones Income Statement — Revenue, Profit & Earnings by Year
Neurones's annual income statement shows how revenue converts into profit each fiscal year, including gross profit, operating income, EBITDA, and net income.
| Fiscal Year | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Total Revenue | €857.20 Million | €810.40 Million | €741.17 Million | €665.38 Million | €579.88 Million |
| Cost of Revenue | €767.13 Million | €421.59 Million | €394.42 Million | €583.74 Million | €510.14 Million |
| Gross Profit | €90.04 Million | €388.76 Million | €346.76 Million | €81.64 Million | €69.73 Million |
| Research & Development | — | — | — | — | — |
| SG&A | — | €437.65 Million | €408.08 Million | €577.45 Million | €170.82 Million |
| Total Operating Expenses | €17.71 Million | €310.84 Million | €270.90 Million | €236.22 Million | €195.00 Million |
| Operating Income | €72.33 Million | €77.90 Million | €75.86 Million | €72.89 Million | €61.57 Million |
| EBITDA | €90.32 Million | €85.92 Million | €96.63 Million | €88.72 Million | €76.23 Million |
| EBIT | €72.33 Million | €77.90 Million | €80.73 Million | €73.31 Million | €61.43 Million |
| Interest Expense | €1.20 Million | €1.65 Million | €1.43 Million | €1.70 Million | €966.00K |
| Income Before Tax | €82.60 Million | €88.10 Million | €80.77 Million | €72.86 Million | €61.76 Million |
| Income Tax Expense | €20.75 Million | €24.90 Million | €22.18 Million | €21.09 Million | €18.82 Million |
| Net Income | €61.90 Million | €52.50 Million | €49.41 Million | €44.24 Million | €37.71 Million |
Neurones Balance Sheet — Assets, Liabilities & Shareholder Equity
The balance sheet below summarizes Neurones's financial position at each fiscal year-end — what it owns (assets), what it owes (liabilities), and the resulting shareholder equity.
| Fiscal Year | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Total Assets | €749.03 Million | €725.69 Million | €674.25 Million | €616.22 Million | €567.82 Million |
| Total Current Assets | €608.53 Million | €588.11 Million | €545.81 Million | €506.57 Million | €464.13 Million |
| Cash & Equivalents | — | — | — | €195.35 Million | €169.60 Million |
| Short-term Investments | — | €276.15 Million | €-65.00K | €195.35 Million | €169.60 Million |
| Net Receivables | €248.92 Million | €216.82 Million | €207.54 Million | €192.23 Million | €165.66 Million |
| Inventory | €700.00K | €267.00K | €709.00K | €353.00K | €887.00K |
| Property, Plant & Equipment | — | €60.53 Million | €58.73 Million | €49.80 Million | €46.10 Million |
| Goodwill | €60.93 Million | €56.53 Million | €51.67 Million | €45.02 Million | €44.41 Million |
| Total Liabilities | €284.16 Million | €289.52 Million | €266.34 Million | €240.63 Million | €214.90 Million |
| Total Current Liabilities | €250.06 Million | €252.66 Million | €228.92 Million | €207.10 Million | €184.56 Million |
| Long-term Debt | — | €2.05 Million | €1.51 Million | €110.00K | €204.00K |
| Net Debt | €-303.82 Million | €-284.47 Million | €-253.78 Million | €-236.49 Million | €-229.85 Million |
| Total Stockholder Equity | €399.98 Million | €378.10 Million | €354.39 Million | €330.58 Million | €311.56 Million |
| Retained Earnings | €371.37 Million | €52.56 Million | €49.41 Million | €288.19 Million | €270.65 Million |
Neurones Cash Flow Statement — Operating, Investing & Financing Activities
This cash flow statement breaks down how Neurones generates and spends cash across operating, investing, and financing activities each fiscal year, including free cash flow and capital expenditures.
| Fiscal Year | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Operating Cash Flow | €80.77 Million | €84.38 Million | €72.08 Million | €54.97 Million | €64.50 Million |
| Capital Expenditures | €10.44 Million | €12.04 Million | €17.98 Million | €10.61 Million | €6.58 Million |
| Free Cash Flow | €70.33 Million | €72.34 Million | €54.09 Million | €44.36 Million | €57.92 Million |
| Investing Cash Flow | €-21.16 Million | €-19.69 Million | €-21.57 Million | €-12.26 Million | €-10.62 Million |
| Financing Cash Flow | €-45.11 Million | €-34.48 Million | €-27.06 Million | €-36.08 Million | €-55.42 Million |
| Dividends Paid | €31.62 Million | €29.13 Million | €26.65 Million | €24.22 Million | €48.42 Million |
| Stock-Based Compensation | — | €5.11 Million | €5.60 Million | €3.36 Million | €1.99 Million |
| Depreciation | €17.99 Million | €17.66 Million | €16.76 Million | €16.57 Million | €14.68 Million |
| Change in Cash | €231.92 Million | €30.57 Million | €23.48 Million | €6.89 Million | €-1.42 Million |
Neurones Earnings History — EPS Actual vs. Analyst Estimates
Track Neurones's quarterly earnings per share (EPS) against Wall Street estimates, along with the earnings surprise percentage for each reporting period.
| Report Date | EPS Actual | EPS Estimate | Surprise |
|---|---|---|---|
| Sep 09, 2026 | — | — | — |
| May 06, 2026 | 0.00 | 0.00 | — |
| Mar 11, 2026 | — | — | — |
| Nov 05, 2025 | 0.00 | 0.00 | — |
| Sep 10, 2025 | 0.93 | 0.00 | — |
| Apr 28, 2025 | 1.15 | 0.00 | — |
| Mar 05, 2025 | 0.00 | 0.00 | — |
| Nov 06, 2024 | 0.00 | 0.00 | — |